  |
         |
 |
 |
| Risk
Sciences International (RSI) | McLaughlin Centre for Population Health Risk Assessment |
University of Ottawa
Pharmacovigilance Workshop
Tabaret Hall, 550 Cumberland Street, Room 083
Friday, January 26, 2007
Pharmacovigilance in Canada
Get
Final Program
Get
Proceedings
Get Workshop Summary
Workshop Particpants
Welcome and Introduction
Daniel Krewski, PhD, MHA, Professor and Director McLaughlin Centre for Population Health Risk Assessment, University of Ottawa & President and CEO Risk Sciences International (RSI)
cphra@uottawa.ca
9:00am
Adverse Drug Reaction Reporting and Signal Detection in Canada
Heather Sutcliffe, Health Canada, Director
Marketed Health Products Safety and Effectiveness Information Bureau
(MHPSEIB)
MHPD_DPSC@hc-sc.gc.ca
9:30am
Future Directions in the Review of Post-Market Safety Data,
Sources of Evidence and Risk Assessment Tools
Lucye Galand, Health Canada, Manager, Scientific
Section, Marketed Pharmaceuticals and Medical Devices Bureau
MHPD_DPSC@hc-sc.gc.ca
10:00am
Risk Communication for Marketed Health Products
Cindy Evans, Health Canada, A/Director, Therapeutic
Effectiveness and Policy Bureau
MHPD_DPSC@hc-sc.gc.ca
10:45am
The Future of Drug Safety
David Korn, MD, Senior Vice President, Biomedical
and Health Sciences Research, Association of American Medical Colleges
& Member IOM Committee on the Assessment of the US Drug Safety System
dkorn@aamc.org
11:30am
Knowledge Findings for Globally Important ADR Signals
I. Ralph Edwards, Professor and Director WHO
Collaborating Centre for International Drug Monitoring, Uppsala Monitoring
Centre, Sweden
1:15pm
Pharmaceutical Use in Pregnancy
Mark Walker MD, Associate Professor, University
of Ottawa & Scientist Ottawa Health Research Institute (OHRI)
mwalker@ohri.ca
1:35pm
Pharmacoepidemilogy
C. Ineke Neutel, PhD, FACE, FISPE, University
of Ottawa
cneutel@uottawa.ca
1:55pm
Spontaneous Adverse Drug Reaction Report Data and Their Potential
for Safety Knowledge Discovery
Alex Ruggieri, MD MHS, Healthcare Executive,
Chief Medical Officer and Senior Director for Safety Solutions, Cerner
Galt
Alex.Ruggieri@Cerner.com
2:15pm
HealthFactsTM Datawarehouse & Active Pharmacovigilance
Doug McNair MD PhD, Sr. Vice President Cerner
LifeSciences
DMCNAIR@CERNER.COM
2:45pm
Panel Discussion «Role of Academia in Pharmacovigilance
in Canada »
Panel Chair: Colleen Metge, BSc (Pharm), PhD, Associate Professor, Faculty of Pharmacy, University of Manitoba
Mark Walker MD, Associate Professor, University of Ottawa & Scientist Ottawa Health Research Institute (OHRI)
Anthony Krantis PhD, Professor, Cellular & Molecular Medicine, Director, Centre for Research in Biopharmaceuticals & Biotechnology (CRBB), Co-Director BIOMECanada Canadian ICC Research Network
akrantis@uottawa.ca
sam.kacew@uottawa.ca
David Clapin, PhD, Branch Science Advisor, Health Canada, Science Coordination and Policy Division
David_Clapin@hc-sc.gc.ca
4:00pm
Pharmacovigilance Workshop Summary
Daniel Krewski, PhD, MHA, Professor and Director
McLaughlin Centre for Population Health Risk Assessment, University
of Ottawa & CEO Risk Sciences International (RSI)
Adjourn
Online presentations from the Pharmacovigilance Workshop are subject to copyright protection. Permission from the speaker is required prior to any copying, reproducing, or rebroadcasiting any portion of the speaker’s presentations.
Workshop Steering Committee
Daniel Krewski, PhD, MHA, Professor and Director McLaughlin Centre for Population Health Risk Assessment, University of Ottawa & CEO Risk Sciences International (RSI)
Daniel Bedard, MSc, Research Coordinator, McLaughlin Centre for Population Health Risk Assessment, University of Ottawa
Vicky Hogan, Risk Process Manager, Office of Risk Management, Health Canada
Doug McNair, MD, PhD, Sr. Vice President Cerner LifeSciences
 |